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A B S T R A C T
The objective of this study was to compare the dosimetric differences of a population-
based planning target volume (PTV) approach and 3 proposed adaptive strategies: plan of
the day (POD), patient-speciﬁc PTV (PS-PTV), and daily reoptimization (ReOpt). Bladder pa-
tients (n = 10) were planned and treated to 46 Gy in 23 fractions with a full bladder in supine
position by the standard strategy using a population-based PTV. For each patient, the adap-
tive strategywas executed retrospectively as follows: (1) POD—multiple distributions of various
PTV sizes were generated, and the appropriate distribution based on the bladder of the day
was selected for each fraction; (2) PS-PTV—population-based PTV was used for the ﬁrst 5
fractions and a new PTV derived using information from these fractions was used to deliver
the remaining 18 fractions; and (3) ReOpt—distribution was reoptimized for each fraction
based on the bladder of the day. Daily dose was computed on all cone beam computed to-
mographies (CBCTs) and deformed back to the planning computed tomography (CT) for dose
summation afterward. V95_Accu, the volume receiving an accumulated delivered dose of 43.7 Gy
(95% prescription dose), was measured for comparison. Mean V95_Accu (cm3) values were 1410
(standard deviation [SD]: 227), 1212 (SD: 186), 1236 (SD: 199), and 1101 (SD: 180) for stan-
dard, POD, PS-PTV, and ReOpt, respectively. All adaptive strategies signiﬁcantly reduced the
irradiated volume, with ReOpt demonstrating the greatest reduction compared with the stan-
dard (− 25%), followed by PS-PTV (− 16%) and POD (− 12%). The difference in the magnitude
of reduction between ReOpt and the other 2 strategies reached statistical signiﬁcance
(p = 0.0006). ReOpt is the best adaptive strategy at reducing the irradiated volume because
of its frequent adaptation based on the daily geometry of the bladder. The need to adapt
only once renders PS-PTV to be the best alternative adaptive strategy.
Crown Copyright © 2018 Published by Elsevier Inc. on behalf of American Association of
Medical Dosimetrists. All rights reserved.
Introduction
The standard treatment formuscle-invasive bladder cancer
is radical cystectomy with bilateral pelvic lymphadenec-
tomy, reporting a 5-year overall survival of 40% to 60%.1
However, for patients who are not suitable for surgery or
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those who prefer to preserve the bladder, radiotherapy has
been offered as part of a multimodality approach, report-
ing a 5-year overall survival rate of 45% to 52%.2-5 The clinical
target volume (CTV) consists of the pelvic lymph nodes
(PLNs), the entire bladder, and the primary tumor.3 A
multiphase treatment regimen is frequently adopted, de-
livering a prescription dose of 40 to 50 Gy to the PLN and
the entire bladder in the ﬁrst phase, followed by a boost of
10 to 20 Gy to the primary tumor alone to minimize the
volume of small bowel being irradiated to high dose.6
Despite the use of cone beam computed tomography
(CBCT) to localize the bladder during radiotherapy, there are
barriers to delivering precision locoregional irradiation due
to the presence of 2 independent moving targets: the PLN,
which is relatively immobile with respect to the bony
anatomy, and the highly distensible bladder, whose volume
and position may vary substantially during a course of ra-
diotherapy. In the presence of 2 independently moving
targets, adaptive radiotherapy has been demonstrated to be
the most eﬃcacious when compared with various image
guidance strategies.7,8
Different adaptive strategies, such as “plan of the day”
(POD),9-19 “patient-speciﬁcplanning target volume (PTV)” (PS-
PTV), 20-22 and daily reoptimization (ReOpt)23 have been
proposed and investigated for bladder radiotherapy to com-
pensate for the large interfraction and interpatient variations
observed. However,most studies have evaluated the eﬃcacy
based on geometric coverage,9,12,15,17-21,24 per-fraction
comparison,13,22 or direct summation of dose-volume
histogram.10,11Moreover, previous studieshaveprimarily com-
pared the differentmethods of generating themultiple PTVs
for the POD strategy10,15,19 or between 2 adaptive strategies.23
Because deformable image registration (DIR) enables the ac-
cumulation of delivered dose to the target and the normal
tissue onto a reference image by tracking the correspond-
ingvoxels betweenmultiple imagedatasets,25-27 itwas applied
in the present study to conduct a dosimetric comparison of
3 adaptive strategies against a standard populationmargin-
basedPTV in assessing their eﬃcacy in reducing the irradiated
volume for locoregional radiotherapy for bladder cancer.
Methods and Materials
Upon local research ethics board approval, patients with
bladder cancer who were prescribed with image-guided ra-
diotherapy to the PLN and the whole bladder between May
2013 and December 2014 were retrospectively identiﬁed.
Any patient who has metallic prosthesis was excluded
because of inferior CBCT image quality induced by the artifact.
This resulted in a total of 10 patients (7 men and 3 women).
All were treated in the supine position with a full bladder
using the standard strategy, in which the PLN and the whole-
bladder CTV contours were used to generate 2 PTVs: the
PTVPLN, by applying a 5-mm expansion on the PLN, and the
standard PTVWB, by applying a 15-mm expansion on the
whole bladder. A 7-ﬁeld IMRT distribution using 6 MV was
generated to deliver 46 Gy in 23 fractions to meet the fol-
lowing evaluation criteria: (1) 99% of PTVPLN and PTVWB
receiving ≥ 43.7 Gy (95% of prescription dose) and (2) 1% of
PTVPLN and PTVWB receiving ≤ 48.3 Gy. The same distribu-
tion was used to deliver all 23 fractions using Synergy XVI
(Elekta Ltd, Crawley, UK). Daily CBCT was acquired for treat-
ment veriﬁcation purposes (M20 collimator, full scan, 120 kV,
40 mA, 40 ms).
To simulate the execution of each adaptive strategy and
to calculate the accumulated delivered dose for compari-
son, the planning computed tomography (CT) and 23 daily
CBCTswere imported into RayStation v.4.5.2 (RaySearch Labo-
ratories, Stockholm, Sweden) and registered using bony
anatomy to reproduce the treatment position. PLN and
whole-bladder contours were delineated by a single ob-
server (V.K.) on each of the 230 CBCTs bymanuallymodifying
the contour propagated from the planning CT.28
Adaptive strategies
PTVPLN remained the same, whereas PTVWB was modi-
ﬁed for each adaptive strategy as follows:
(1) POD18: Four PTVWB (PTVWB0, PTVWB5, PTVWB10, and PTV
WB15) were constructed by uniformly expanding the
whole-bladder CTVby0, 5, 10, and15mm. Thismethod
resulted in a total of 4 IMRT distributions in the POD
library for eachpatient. Selectionof the “treatment PTV”
was simulated by choosing the smallest PTVWB that en-
compassed the bladder visualized on each of the 23
CBCTs. The dose for each fractionwas computed on the
CBCT based on the PTVWB distribution selected.
(2) PS-PTV21: PS-PTVWB was derived by applying a 5-mm
expansion on a combination of the whole-bladder CTV
contours from the planning CT and the ﬁrst 5 CBCTs
(Fig. 1). The dose for the ﬁrst 5 fractions was com-
puted on the ﬁrst 5 CBCTs using the PTVPLN + standard
PTVWB distribution, and then a new distribution was
created based on PTVPLN and PS-PTVWB and was cal-
culated on the remaining 18 CBCTs.
(3) Daily ReOpt23: The whole-bladder CTV contour on each
of the 23 CBCTs was expanded by 5 mm to generate
23 PTVWB. The PTVPLNwas propagated from the planning
CT onto the CBCT and combined with each PTVWB to
construct a daily ReOpt-PTV. The beam conﬁguration
and optimization objectives used for generating the
initial standard dose distribution were used to
reoptimize the dose distribution and to deliver a daily
fractional dose of 2 Gy to the ReOpt-PTV on each of the
23 CBCTs.
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Dose accumulation
CT-CBCT DIR was performed using the Anatomically Con-
strained Deformation Algorithm (ANACONDA),29 creating a
deformation map for each CBCT. Bladder and the PLN were
used as the guiding structures for the registration to improve
the quality of the output.30 After assigning the CBCT density
number using the auto setting in the treatment planning
system (Fig. 2), the fractional dose computed on each CBCT
was then mapped onto the planning CT, based on the DIR
output. These mapped daily doses were then summed for
each adaptive strategy.
Data collection and statistical analysis
The V95_Accu (volume irradiated to an accumulated dose of
43.7 Gy [95% of prescription dose]) were obtained for each
patient. The ratio of normal tissue encompassed by V95_Accu
(NTinV95_Accu) to V95_Accu was calculated as another metric to
evaluate the eﬃcacy of the adaptive strategies in reducing
normal tissue irradiation. One-way analysis of variance was
used to determine the difference between the standard PTV
and the adaptive strategies, and paired t-test was used when
comparing 2 strategies. p < 0.05 was considered statistical-
ly signiﬁcant. The percentage difference from the standard
V95_Accu to each adaptive strategy was calculated to evalu-
ate its eﬃcacy in reducing the treatment volume. In addition,
pairwise analysis on individual patients was conducted to
facilitate comparison.
Results
A total of 10 planning CTs and 230 CBCTs from 10 pa-
tients with bladder cancer were included in the present study,
resulting in 40 V95_Accu volumes for comparison. Overall, the
treatment bladder volume was smaller than the planning
scan volume, with amedian treatment/planning volume ratio
of 0.51 (range: 0.43 to 0.87). Nevertheless, an equivalent or
larger bladder volume was achieved for 27% of the frac-
tions. There was large variation among patients in the
magnitude of interfraction volume changes (Fig. 3). However,
no correlation was observed between the initial planning
bladder volume and the magnitude of daily variation.
The dose from each fraction was deformed back to the
reference CT for total dose accumulation. Without any ad-
aptation, V95_Accu of the standard was 1472 cm3 (standard
deviation [SD]: 227 cm3). This valuewas signiﬁcantly reduced
to a mean volume (cm3) of 1294 (SD: 186), 1234 (SD: 199),
and 1102 (SD: 180) by POD, PS-PTV, and ReOpt, respective-
ly, translating to a median reduction of 13%, 14%, and 29%
Fig. 1. Schematic representation of PS-PTV generation. The planning
bladder (black solid line) and the 5 CBCT bladders (dashed lines) were
combined to form the occupancy volume (red). Fivemillimeters was added
to generate the PS-PTV. (Color version of ﬁgure is available online.)
Fig. 2. Axial and sagittal views displaying the assignment of CBCT density. The mass density of adipose tissue and cartilage and bone were (g/cm3)
0.95, 1.05, and 1.6, respectively. (Color version of ﬁgure is available online.)
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from the standard V95_Accu (p = 0.002) (Fig. 4). The reduction
by ReOpt was signiﬁcantly greater than the other 2 strate-
gies (p = 0.0006), and the V95_Accu reduction by PS-PTV was
greater than that by POD (p < 0.05).
The proportion of normal tissue in V95_Accuwas the highest
for standard, with a mean NTinV95_Accu/V95_Accu ratio of 0.63
(SD: 0.05). All 3 adaptive strategies signiﬁcantly reduced the
ratio to a mean of 0.50 to 0.58, with ReOpt being the most
superior (p < 0.05). Using the standard as the reference, the
NTinV95_Accu was reduced by a median of 43%, 21%, and 20%
by ReOpt, POD, and PS-PTV, respectively. The magnitude of
improvement among adaptive strategies were signiﬁ-
cantly different (p = 0.0003).
The relative V95_Accu reduction from the standard by each
of the adaptive strategies for patient no. 6 is shown in Fig. 5.
The greatest improvement was in the inferior portion, which
was common for all patients. Dose reduction was also fre-
quently seen in the superior-anterior aspect, particularly with
the ReOpt strategy.
Interpatient comparison
ReOpt was able to achieve the smallest V95_Accu for all pa-
tients except for patient no. 7 and patient no. 5 (Fig. 6). The
per-patientmagnitude of reduction from the standard ranged
from 8% to 35% (Table 1). Patient nos. 4, 6, and 9 beneﬁted
most from ReOpt in this cohort with a magnitude of reduc-
tion greater than the upper quartile of 32%. These 3
individuals all had a treatment/planning bladder volume ratio
smaller than the median of 0.51. PS-PTV was the second best
adaptive strategy for 7 of 10 patients.
Fig. 3. The planning bladder volume (cm3) of the individual patients (black dots), along with the corresponding median, interquartile range, and full
range of treatment/planning bladder volume ratios (box and whisker).
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Fig. 4. Mean and range of V95_accu (left); % decrease in V95_accu by the adaptive strategies compared with standard (right).
ARTICLE IN PRESS
4 V.C. Kong et al. / Medical Dosimetry ■■ (2018) ■■–■■
Discussion
Using the subject as their own control, 3 adaptive strat-
egies were applied to 10 patients with bladder cancer to
calculate the delivered dose for comparison against a
nonadaptive approach. This is the ﬁrst study to evaluate the
eﬃcacy of 3 different adaptive strategies for the treatment
of the PLN and the bladder.
All 3 proposed adaptive strategies signiﬁcantly reduced
the irradiated volume compared with the standard, with
ReOpt being the most eﬃcacious among the strategies. The
magnitude of V95_Accu reduction with ReOpt was signiﬁ-
cantly greater than both the PS-PTV and the POD because
of its ability to adjust to the changes in the position and the
volume of the bladder. This ﬁnding is consistent with that
of the only study published to date that compared the ef-
ﬁcacy of ReOpt with the POD strategy. Using 7 patients in
the study, Vestergaard et al. reported a mean reduction of
59% with ReOpt compared with the nonadaptive approach
and this rate was noted to be signiﬁcantly greater than the
34% attained by POD.23 The improvement by either the ReOpt
or the POD in Vestergaard et al. was much greater than the
results presented in this study, in which the median reduc-
tions were 29% and 12%. This result could be due to the
inclusion of PLN, along with the bladder, as the treatment
volume in this study, as the magnitude of improvement by
Fig. 5. Sagittal view of patient no. 6 displaying the bladder (yellow line) and the distribution of the dose reduction (color wash) from the standard
by (A) POD, (B) PS-PTV, and (C) ReOpt. Magnitude of reduction represented by color wash—red (50%), orange (40%), yellow (30%), green (20%), and
blue (10%). (Color version of ﬁgure is available online.)
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Fig. 6. Comparison of V95_Accu among the standard and the 3 adaptive strategies.
Table 1
Treatment/planning bladder volume ratio of individual patients alongwith
the corresponding percentage decrease from the standard V95_Accu for each
adaptive strategy
Patient Treatment/planning
bladder volume ratio
% Decrease from standard V95_Accu
ReOpt PS-PTV POD
8 0.43 29 10 14
4 0.46 35 23 17
6 0.46 32 12 14
9 0.47 32 22 12
3 0.51 25 14 9
7 0.51 8 15 6
2 0.55 16 12 8
5 0.70 12 13 14
1 0.79 29 16 10
10 0.87 29 25 15
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any adaptive strategy had been reported to be smaller when
PLN was included.11,14 Unlike the bladder, in which modiﬁ-
cation of the PTVWB is required to account for the signiﬁcant
geometric variations, the PTVPLN remains the same, hence re-
ducing the effect of the adaptive strategies. The smaller
margin used to construct the standard PTV for the bladder
in this study (15 mm vs 20 mm in Vestergaard’s study) also
may have contributed to a smaller magnitude of improve-
ment reported herein.
The present study found large interpatient variation in
the magnitude of V95_Accu volume reduction, with the largest
reduction seen for ReOpt, followed by PS-PTV and POD. In
Vestergaard’s study, however, POD exhibited a greater degree
of interpatient variation than ReOpt.23 This ﬁnding could be
due to the different bladder ﬁlling protocol used for plan-
ning and treatment. Full bladder was adopted for planning
and treatment in the present study, and despite speciﬁc in-
structions, large interfraction variation in bladder ﬁlling was
reported. By creating a new distribution based on the bladder
ﬁlling of the day, ReOpt achieved a greater V95 reduction for
patients exhibiting larger bladder ﬁlling changes than those
who could achieve a more consistent bladder volume. This
ﬁnding may explain the differences between the present
study and Vestergaard et al., who used an empty bladder pro-
tocol, and reported a more consistent bladder volume and
shape. Alternatively, the differences in the ﬁndings could be
attributed to the different methods used in generating the
POD library between the 2 studies. In this study, a uniform
expansion in 5-mm increments was applied to the plan-
ning bladder to construct various PTVWB for the POD library,
whereas these volumes were derived based on patient-
speciﬁc information from the ﬁrst few treatment fractions
in Vestergaard et al. The latter method would account for
additional variation and therefore would result in a larger
range of interpatient variations.
Despite adapting only once after the ﬁfth fraction, PS-
PTV was able to achieve a greater reduction in V95 than POD.
There were 3 patients5,6,8 in which PS-PTV was noted to be
comparable or inferior to POD, which could be attributed to
a similar shape and volume between the PS-PTV and the
PTVs in the POD. Figure 5A displays the sagittal view of
patient no. 8. Despite a smaller bladder in the ﬁrst 5 frac-
tions, the PS-PTV was enlarged by the inclusion of the
planning bladder in its construction. With PTVWB5 being se-
lected for 91% of the fraction for this patient, the outcome
between the 2 strategies was therefore comparable. Simi-
larly, the volume of PS-PTV of patient no. 6 was augmented
by the inclusion of a much larger bladder from the fourth
fraction, weakening its volume sparing effect in subse-
quent fractions (Fig. 7B). As the inclusion of an “outlier”
volume was shown to affect the eﬃcacy of PS-PTV, exclu-
sion of these volumes should be considered to derive a PS-
PTV that is more reﬂective of the bladder geometry for the
remaining fractions.
There are several strengths and limitations in the present
study. Although there were only 10 patients included, it can
be considered a good representation of the anatomical vari-
ation of the population through the inclusion of both male
and female patients. In addition, the sample size was one
of the largest among studies in which dose accumulation had
been performed for evaluation.14,16,23 Patients were in-
structed to have a comfortably full bladder for planning and
treatment in the present study, and hence, the magnitude
of improvement observed in this study may vary if pa-
tients were planned and treated with an empty bladder.
Many institutions adopt the empty bladder protocol for better
reproducibility, patient comfort, and minimizing the irra-
diated volume.9,12,15,17,22,23 There are several reasons for
supporting the use of full bladder. First, studies have indi-
cated that there were no signiﬁcant differences in motion
Fig. 7. (A) Sagittal view of patient no. 8. Despite a small bladder volume on CBCT 1 to 5 (green), PS-PTV (pink) was expanded in the anterior-
superior direction because of the inclusion of the planning bladder (yellow). The resultant shape and volume were comparable with PTVWB5 (blue).
(B) Sagittal view of patient no. 6. Fx 4 bladder (blue) was much larger than the planning (yellow) and the bladder from Fx 1 to 3 and 5 (blue), re-
sulting in a large PS-PTV (pink). (Color version of ﬁgure is available online.)
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of the bladder wall using full or empty preparation, and
therefore, the samemargin could be applied.21,31 Second, there
is a substantial dosimetric beneﬁt to using full bladder prep-
aration to maximize sparing of a normal bladder wall when
partial bladder irradiation is prescribed for some cases.14
Third, smaller bladder volumes have demonstrated greater
intrafraction motion due to ﬁlling, necessitating a larger
margin to account for the changes.32 Patients would also ex-
perience diﬃculty achieving an empty bladder toward the
end of treatment because of swelling, toxicity, and admin-
istration of concurrent chemotherapy. This ﬁnding was
demonstrated in Webster’s study, in which PS-PTV derived
based on an empty bladder resulted in poor target cover-
age because of a larger treatment bladder in later fractions.24
The isotropic margin and the method used to generate the
POD library in the present study are also recognized as a lim-
itation in generalizing the ﬁndings. Many methods of
generating the POD library have been reported,9-19,22 and the
eﬃcacy of each method against the other 2 adaptive strat-
egies needs to be further investigated.
Conclusions
The large and random variation in bladder volumes ob-
served in this cohort of patients beneﬁted from the use of
any of the proposed adaptive strategies, especially when the
treatment bladder volumeswere predominantly smaller than
the planning bladder volume. Dosimetric improvements
using ReOpt were the most signiﬁcant, because of the meth-
od’s ability to provide adequate target coverage with
maximum sparing of normal tissue. However, the resource
burden associated with this strategy was substantial, lim-
iting its application in a clinical environment with the current
technology. On the other hand, the need to adapt only once
renders PS-PTV to be the best alternative adaptive strategy
and has been implemented at our institution to improve
treatment quality.
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